Aug 11, 2020
Although biosimilars have been proven to have equivalent efficacy and no clinically meaningful differences in safety and immunogenicity from their reference products, its use in rheumatology has generated much debate among clinicians, patients, drug manufacturers, and payers. While several of these biopharmaceuticals...